Ally Bridge
Deal focus: NiKang pursues hard-to-drug targets
With big pharma scaling back early-stage discovery, CBC Group is keen to incubate biotech start-ups developing drugs from scratch. NiKang Therapeutics is the first to secure wider investor attention
Singapore biotech start-up closes $125m Series C
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has led a $125 million Series C round for Hummingbird Bioscience, a Singapore and US-based drug developer.
AVCJ Awards 2019: Exit of the Year - IPO: Innovent Biologics
Innovent Biologics has set a new standard for Chinese biotech, securing an innovative drug development tie-up with Eli Lilly and then completing a successful Hong Kong listing
China's I-Mab falls on US debut after $104m IPO
China-based I-Mab Biopharma traded as much as 12% lower than initial pricing following the private equity-backed company’s $104 million IPO in the US.
China's I-Mab Biopharma pursues US IPO
I-Mab Biopharma, the product of a CBC Group-engineered merger of two Chinese drug developers, has announced plans for a NASDAQ IPO.
PE-backed Hansoh Pharma completes $1b Hong Kong IPO
Hansoh Pharmaceutical Group, a Chinese drug developer that counts Hillhouse Capital and Boyu Capital among its investors, has raised HK$7.86 billion ($1 billion) through a Hong Kong IPO.
Hillhouse-backed CRO Frontage raises $205m in HK IPO
Frontage Holdings, a China-based contract research organization (CRO), has raised HK$1.61 billion ($205.1 million) in its Hong Kong IPO, having received support from several private equity investors.
PE-backed Jinxin Fertility files for HK IPO
Jinxin Fertility, the assisted reproduction services division of China’s Jinxin Group that is backed by several private equity investors, has filed for an IPO in Hong Kong.
PE-backed WuXi Apptech trades flat on Hong Kong debut
PE-backed WuXi AppTec, a contract pharmaceutical R&D services provider, traded flat on its Hong Kong debut, following an IPO of HK$9.1 billion ($1.1) billion.
US-China biotech: Troubled transfers
Chinese investment in US biotech – and its ability to import intellectual property for domestic drug development – looks set to be a casualty of worsening relations between the two nations
PE-backed WuXi AppTec targets Hong Kong listing
Wuxi AppTec, a contract pharmaceutical R&D services provider backed by several private equity investors, has filed for a Hong Kong listing less than four months after listing in Shanghai. The size and pricing of the IPO have yet to be decided, but the...
Cancer drug developer Innovent Biologics files for HK IPO
Innovent Biologics, a Chinese drug developer company with a number of PE backers, has filed for an IPO in Hong Kong under recently introduced rules allowing listings by biotech companies with no revenue or profits.
Hua Medicine files for HK IPO under biotech fastrack
Hua Medicine, a Chinese drug developer player that simultaneously closed its Series D and E funding rounds in March, has become the second company to file for a Hong Kong IPO under rules that allow zero revenue biotech businesses to go public.
Chinese VCs join $300m round for US, Hong Kong-based Grail
Ally Bridge Group, Hillhouse Capital and 6 Dimensions Capital have co-led a $300 million Series C round for Grail, a biotechnology development firm based in Hong Kong and the US.
Capital Group leads Series E for China’s Innovent Biologics
Capital Group Private Markets (CGPM), a private equity affiliate of US-based Capital Group Companies, has led a $150 million Series E round for Chinese biopharmaceutical developer Innovent Biologics.
China’s Hua Medicine gets $117m
Hua Medicine, a Chinese clinical-stage biotechnology company, has closed a combined Series D and Series E funding round at $117.4 million with support from a group of VCs.
PE-backed WuXi Biologics completes Hong Kong re-listing
WuXi Biologics, a Chinese contract R&D services provider to the global pharmaceutical industry that was taken private by a PE-backed consortium in late 2015, gained 38% on its Hong Kong trading debut following a HK$3.97 billion ($510 million) IPO.
CDB Capital leads $42m round for China fintech firm Wacai
CDB Capital, the fund management arm of China Development Bank, has led a $42 million round for Wacai, a Chinese finance management mobile app developer.
Ally Bridge backs $301m Luoxin Pharma take-private
Healthcare-focused PE investor Ally Bridge Group will support the HK$2.3 billion ($301 million) management-led take-private of Hong Kong-listed Shandong Luoxin Pharmacy Group.
Cross-border VC: Changes in the wind
US-China cross border investment continues to present exciting opportunities for venture capital firms targeting technology start-ups, but investors must keep up with the pace of the market’s transformation
China GPs underline merits of sector focus
China GPs must respond to the country’s economic slowdown by paying closer attention to picking sectors that can outperform – and in which they can help drive that performance – industry participants told the Hong Kong Venture Capital & Private...
Deal focus: Hua Medicine gets cross-border injection
Following its $50 million Series C round, investors in Hua Medicine are waiting for the company to fulfill its potential as a poster child of innovation in China
Harvest leads $50m round for China’s Hua Medicine
Harvest Fund Management has led a $50 million Series C round – which was more than 3x oversubscribed – for China-based clinical-stage diabetes treatment developer Hua Medicine.
Ally Bridge leads $150m round for US cancer treatment firm
San Diego-based cancer treatment developer Sorrento Therapeutics has raised about $150 million from a group of investors led by China-focused healthcare specialist Ally Bridge Group.